Asian Development Bank approves $3 million grant to India to combat COVID-19

The grant, which is financed by the Japanese government, will be used to procure thermal scanners and essential commodities to strengthen the India's COVID-19 response, Asian Development Bank (ADB) said in a statement.

July 29, 2020 / 02:20 PM IST
Representative Image

Representative Image

Multilateral funding agency Asian Development Bank (ADB) on Wednesday said it has approved USD 3 million (about Rs 22 crore) grant to India from its Asia Pacific Disaster Response Fund to further support the government's emergency response to COVID-19 pandemic.

The grant, which is financed by the Japanese government, will be used to procure thermal scanners and essential commodities to strengthen the India's COVID-19 response, ADB said in a statement.

"The new grant complements ADB's ongoing support to the Government of India in strengthening its COVID-19 response. This support will enhance disease surveillance and help in early detection, contact tracing, and treatment. This will be further supplemented by other public health measures," it said.

On April 28, ADB approved USD 1.5 billion COVID-19 Active Response and Expenditure Support (CARES) programme to support India in its immediate pandemic response efforts, including disease containment and prevention, as well as social protection measures for the poor and economically vulnerable, particularly women and disadvantaged groups.

The CARES programme is funded through the COVID-19 pandemic response option (CPRO) under ADB's Counter-cyclical Support Facility.

Close

COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more
Show

CPRO was established as part of ADB's USD 20 billion expanded assistance for developing member countries' pandemic response, which was announced on April 13.

(With PTI inputs)
Moneycontrol News
first published: Jul 29, 2020 01:57 pm

stay updated

Get Daily News on your Browser
Sections